XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

9 Months Ended

Sep. 30, 2015

Condensed Consolidated Financial Statements Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Common stock options and RSUs		10,972		8,037		9,623		6,601
Warrants for common stock		18,166		1,910		18,166		1,910
Total		29,138		9,947		27,789		8,511

Reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock

The following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Numerator
Net loss
Basic	$	(480	)	$	(14,399	)	$	(45,958	)	$	(30,983	)
Adjustment for revaluation of contingent warrant liabilities		—			(5,360	)		—			(32,510	)
Diluted	$	(480	)	$	(19,759	)	$	(45,958	)	$	(63,493	)

Denominator
Weighted average shares outstanding used for basic net loss per share		118,552			107,208			117,437			106,768
Effect of dilutive warrants		—			7,115			—			8,108
Weighted average shares outstanding and dilutive securities used for diluted net loss per share		118,552			114,323			117,437			114,876

Accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

	September 30, 2015		December 31, 2014
Accrued payroll and other benefits	$	2,965	$	3,061
Accrued management incentive compensation		2,663		4,295
Accrued restructuring costs		1,742		—
Accrued clinical trial costs		576		1,424
Other		1,734		1,112
Total	$	9,680	$	9,892